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ABSTRACT
Objectives: Patients with rheumatoid arthritis (RA) have
increased cardiovascular mortality. Tumour necrosis factor
a (TNFa)-blocking therapy has been shown to reduce RA
disease activity measures and joint damage progression.
Some observational studies suggest that TNFa blockade
reduces mortality and incidence of first cardiovascular
events. The mechanisms contributing to these outcomes
are unclear. This study assessed the effects of infliximab
treatment on vascular stiffness and structure in patients
with RA.
Methods: A post hoc analysis of longitudinal data from a
randomised placebo controlled study evaluated the effect
of infliximab on vascular assessments. 26 patients
received intravenous infliximab (3 mg/kg) at weeks 0, 2, 6
and every 8 weeks thereafter to week 54. Patients were
followed up to 56 weeks of infliximab therapy with
assessments of RA disease activity, cardiovascular risk
factors, vascular stiffness (pulse wave velocity (PWV)),
carotid intima media thickness (CIMT) and carotid artery
plaque (CAP). Univariate analyses of changes over time by
repeated measures analysis of variance (ANOVA) were
followed by multivariate time-series regression analysis
(TSRA) if changes were seen.
Results: PWV was significantly lower (better) after
56 weeks of treatment with infliximab (ANOVA p,0.01,
TSRA p,0.01). However, CIMT (ANOVA p=0.50) and
CAP (x
2=4.13, p=0.88) did not change over the study
period. Multiple cardiovascular risk measures did not
change with treatment and did not correlate with changes
in measures of vascular structure.
Conclusions: Arterial stiffness improves with infliximab
treatment in RA. This change may help explain the
improved cardiovascular disease survival in patients with
RA receiving TNFa-blocking therapy.
Rheumatoid arthritis (RA) is associated with
increased cardiovascular morbidity and mortality.
1
Patients with RA have a higher risk of cardiovas-
cular events
23not explained entirely by traditional
cardiovascular risk factors,
4 implying that cardio-
vascular disease is an extra-articular manifestation
of RA.
5
Tumour necrosis factor a (TNFa) is a pro-
inflammatory cytokine central to the pathology
of RA and may also promote vascular disease.
67
TNFa-blocking drugs reduce inflammation and
joint damage in RA,
8–11 and may reduce mortality
12
and cardiovascular disease.
13 14 Data indicate that
patients responding to TNFa-blocking therapy
within the first 6 months have a greater reduction
in the incidence of myocardial infarction compared
with non-responders.
15 Surrogate vascular measures
have been used to indicate early atherosclerosis and
predict increased future cardiovascular risk.
Increased arterial stiffness, increased carotid intima
media thickness (CIMT) and endothelial dysfunc-
tion have been demonstrated in patients atincreased
risk of and with known cardiovascular disease.
16 17
They have also been found to be independent
predictors of future cardiovascular events.
18 19
Carotid-femoral pulse wave velocity (PWV) is now
used as a therapeutic end point in studies of
antihypertensive treatments.
20 All of these measures
have been reported to be abnormal in patients with
RA.
21–23 Improvement in arterial stiffness has been
reported in RA after TNFa-blocking therapy with
etanercept.
24 Previous reports of CIMT in response
to TNFa blockade indicate mixed results.
21 25
There is conflicting evidence regarding the roles
of conventional cardiovascular risk factors in the
pathogenesis of atherosclerosis in RA. Oxidised
low-density lipoprotein (LDL) is thought to be
particularly atherosclerogenic.
26 Adiponectin is an
adipokine associated with the metabolic syndrome
and possibly with accelerated atherosclerosis.
27 The
relationship of these two factors with athero-
sclerosis in the setting of RA has not been
evaluated.
This longitudinal study examined the effects of
infliximab on vascular stiffness and structure in
patients with RA and measured changes in multi-
ple risk factors for atherosclerotic disease including
oxidised LDL and adiponectin. We evaluated this
initially as a randomised controlled trial and then
undertook a post hoc re-evaluation when the entire
cohort received infliximab.
METHODS
Patients
Adult subjects (>18 years) with RA defined by
American College of Rheumatology criteria
28
referred for TNFa-blocking therapy according to
the British Society of Rheumatology (BSR) criteria
were recruited from outpatient clinics at Guy’s and
St Thomas’ Hospitals between January 2004 and
June 2005. Patients were invited to participate if
they had failed on two disease-modifying anti-
rheumatic drugs including methotrexate, and had a
disease activity score 28 (DAS28) .5.1 on two
occasions at least 4 weeks apart. All patients were
taking methotrexate ((25 mg/week). All anti-
rheumatic medications remained stable for at least
4 weeks preceding and during the study unless
changes in dose were medically indicated.
Exclusion criteria were chosen in an effort to
exclude patients with traditional cardiovascular
risk factors or drug treatments that may confound
results. Patients were therefore excluded from the
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cerebrovascular disease, peripheral vascular disease, diabetes
mellitus, treatment with aspirin or prednisolone at a dose
.10 mg/day and previous treatment with infliximab or any
therapeutic agent targeted at TNFa. Patients with evidence of
current or previous infection with tuberculosis, regardless of
previous treatment, were excluded.
Protocol
In a randomised, placebo controlled, double-blind study,
patients were allocated using a 2:1 randomisation procedure
to infliximab or placebo. Infliximab 3 mg/kg was administered
by intravenous infusion at weeks 0, 2, 6 and every 8 weeks
thereafter for a total of 54 weeks. Patients randomised to
placebo received saline infusions for the first 22 weeks and
switched to open-label infliximab at week 24. Patients in the
placebo group with worsening RA disease activity at week 14
were permitted to escape to open-label infliximab at week 16.
The primary outcome measures were vascular ultrasound
assessments at weeks 24 and 56 (2 weeks after infusions to
assess maximal improvement). Secondary outcome measures
included RA disease activity and cardiovascular risk factors.
Assessment of RA disease activity
RA disease activity was assessed at baseline, 8, 16, 24, 40 and
56 weeks by the modified Health Assessment Questionnaire
(HAQ),
29 28 swollen and tender joint counts, erythrocyte
sedimentation rate (ESR), patient global assessment using a
100 mm visual analogue scale and DAS28.
30
Assessment of cardiovascular risk factors
Cardiovascular risk factors included systolic and diastolic blood
pressure (BP), C-reactive protein (CRP), serum fasting lipid
profile (total cholesterol, high- and low-density lipoprotein
fractions (HDL, LDL) and triglycerides), oxidised LDL, insulin
resistance measured by log homeostasis model assessment
(HOMA)
31 and adiponectin.
27 Subjects who had smoked within
the last 2 years were categorised as current smokers. BP, heart
rate and HsCRP were assessed at baseline, 8, 16, 24, 40 and
56 weeks. Lipid profiles and HOMA were measured at 0, 24, 40
and 56 weeks and adiponectin at 0, 24, 40 and 56 weeks.
Vascular assessments
BP and assessment of vascular stiffness (PWV), structure
(CIMT), augmentation index (AI) and carotid artery (athero-
sclerotic) plaque (CAP) were measured in supine fasting subjects
in a quiet room with temperature controlled to 22uC.
Antihypertensive, anti-inflammatory and cyclo-oxygenase-2
inhibitor medications were withheld 24 h before assessment.
BP was measured using an Omron BP monitor. The mean of
three measurements was recorded for each vascular assessment.
The ultrasonographer was blind to the treatment status of the
patients during the randomised controlled phase of the study.
Arterial stiffness: pulse wave velocity (PWV)
Carotid-femoral PWV was measured at baseline and after 24
and 56 weeks of treatment as the time delay between the rapid
upstroke of the carotid and femoral artery pulse waves using the
PWA system (SphygmoCor, PWA Medical, Sydney, Australia).
The distance between the two arterial points was measured on
the surface of the body using a tape measure. PWV was
calculated as the distance travelled by the arterial pulse wave in
metres divided by the time delay between the two arterial
points in seconds (intra-observer reliability ICC=0.84, N=12
subjects with RA).
Arterial structure: carotid intima media thickness (CIMT)
CIMT was measured at weeks 0 and 56 using ECG-triggered
high-resolution duplex ultrasonography (Acuson XP10) with a
7.5 MHz vascular probe. Measurements were performed on the
common carotid arteries 1–2 cm proximal to the bulb and
studied in longitudinal and transverse planes with anterior,
lateral and posterior approaches. The average of the measure-
ments of the anterior, lateral and posterior projections of the far
wall performed on each side was used to calculate the CIMT for
each subject (intra-observer reliability ICC=0.98, N=12
subjects with RA).
Augmentation index (AI)
AI is a method of pulse wave analysis (PWA) performed using
applanation tonometry of the radial artery (PWA system,
SphygmoCor); it was measured at weeks 0, 24 and 56. The
PWA system acquires 10–12 sequential waveforms and gen-
erates an averaged radial and mathematically-derived corre-
sponding central aortic waveform. AI is derived from the
estimated aortic waveform and is defined as the increase in
pressure from the first systolic peak/shoulder to the second
systolic peak/shoulder expressed as a percentage of pulse
pressure (intra-observer reliability ICC=0.86, N=8 subjects
with RA).
Carotid artery plaque (CAP)
CAP was measured by ultrasound at weeks 0, 24 and 56. A grade
of 0 was assigned for no plaque, 1 for minimal plaque and 2 for
extensive plaque. A combined score for the right and left carotid
arteries was calculated as the sum of the right and the left scores
for each individual subject on a scale of 0–4.
Statistical analysis
Sample size calculation
The sample size was estimated for a 2:1 (infliximab: placebo)
randomised controlled trial using unpublished paired assess-
ments of PWV in 12 patients with RA (mean 8.88, s 2.12 m/s
(first assessment) and reliability ICC 0.84. Smallest detectable
difference (D) was calculated as 3.23,
32 giving a required sample
size of six patients per group (a=0.05, power=0.80).
Assuming a 30% drop-out rate, we aimed to recruit 9 patients
for placebo and 18 for treatment.
Intention-to-treat analysis
Assessments of RA disease activity, BP and heart rate were
compared between subjects in the treatment and placebo arms
by a two-sided Student t test at 0, 8 and 16 weeks. Follow-up
vascular assessments were not performed within the 16-week
placebo controlled phase and, as such, could not be included in
the analysis.
Post hoc analyses
Post hoc multivariate ANOVA modelling was performed to
evaluate the effects of treatment with infliximab (vs placebo)
and duration of treatment (0 vs 8 vs 16 weeks) on disease
activity, systolic and diastolic blood pressure and heart rate
during the initial controlled part of the trial.
Because all subjects in the placebo arm elected to ‘‘escape’’ to
the treatment arm at 16 weeks, a second post hoc analysis was
performed to evaluate trends in all subjects over time during
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baseline infliximab assessment was at the end of the placebo
controlled phase at 16 weeks, the 8-week assessment was at
week 24, the week 24 assessment was at week 40, and the week
40 assessment was at week 56. Preliminary univariate analysis
was performed to identify possible changes during infliximab.
For continuous data the changes over time from pretreatment
to 24 and 56 weeks were evaluated by repeated measures analysis
of variance (RM ANOVA) with time point comparisons using
Bonferroni-corrected t tests. Assessments of CAP, being catego-
ricaldata,wereevaluatedbythex
2test.Vascularassessmentsthat
changed during infliximab therapy were further explored for
possible confounding influences by simple correlation followed by
time-series regression analysis with linear random intercepts
models accounting for clustering within individuals. In this
analysis we used all available observations preceding and during
infliximab treatment. Potentially modifiable cardiovascular risk
factors that correlated with the vascular assessment at baseline
with r.0.20 were evaluated.
The study database was generated by the Trial Coordination
Center (TCC), Groningen, The Netherlands. All entries were
double-entered to ensure complete and accurate data capture,
and all data queries answered before the database was cleaned
and locked. Statistical analysis was performed using Stata
Version 6.0 (Statacorp, Texas, USA).
RESULTS
Twenty-six subjects were enrolled in the study; 17 were
randomised to infliximab and 9 to placebo. All 9 subjects in
the placebo arm elected to take the escape arm after 14 weeks. A
greater proportion of patients in the treatment arm were
rheumatoid factor positive, otherwise baseline characteristics
were similar across the groups (table 1).
Intention-to-treat analysis
The results for the placebo controlled double-blind phase of the
study are shown in fig 1. Tender and swollen joint counts,
patient global assessments and DAS28 scores were all signifi-
cantly lower in the treatment arm by 8 and 16 weeks. ESR was
significantly better in the treatment arm at 8 weeks but not at
16 weeks. Heart rate, CRP, systolic and diastolic BP were not
significantly different at 8 or 16 weeks. Arterial stiffness, lipid
profiles, HOMA and adiponectin were not assessed during the
placebo controlled phase of the study.
Post hoc analysis
Post hoc multivariate ANOVA modelling of the initial
controlled phase of the trial confirmed the effect of treatment
on disease activity (DAS28, ESR, tender and swollen joint
counts) but not heart rate, systolic and diastolic BP. In the
Table 1 Baseline patient characteristics
Infliximab
(n=17)
Placebo
(n=9) Test p Value
Total
Mean SD Range
Demographics
Gender (proportion female) 14/17 8/9 x
2 test 0.660 22/26
Age (years) 48 (12) 50 (16) t test 0.663 49 (14) 29–77
Vascular assessments
PWV (m/s) 8.8 (1.4) 9.4 (2.3) t test 0.438 9.0 (1.7) 6.5–12.7
Mean CIMT (mm) 0.9 (0.3) 0.9 (0.3) t test 0.709 0.9 (0.3) 0.4–1.6
CAP (number with each
combined grade 0/1/2/3/4)
9/4/2/1/1 7/0/0/2/0 x
2 test 0.226 16/4/2/3/1
RA disease activity
RF-positive (proportion) 7/16 7/8 x
2 test 0.040 14/24
ESR (mm/h) 39 (26) 40 (24) t test 0.882 39 (24) 3–88
CRP (mg/l) 32 (47) 30 (21) t test 0.898 32 (39) 4–186
Patient global assessment
(100 mm)
68 (15) 70 (25) t test 0.829 69 (18) 37–100
Tender joint count
(out of 28)
14 (7) 15 (7) t test 0.837 14.5 (6.8) 3–26
Swollen joint count
(out of 28)
10 (5) 12 (5) t test 0.286 10.5 (5.1) 3–21
DAS28 6.2 (0.9) 6.4 (0.8) t test 0.554 6.3 (0.8) 5.2–7.9
Cardiovascular risks
Smoking status (non/ex/
current), N
9/5/3 5/3/1 x
2 test 0.905 14/8/4
Heart rate (beats/min) 69 (11) 72 (11) t test 0.570 70 (11) 47–90
Systolic BP (mm Hg) 121 (14) 124 (18) t test 0.642 122 (15) 97–153
Diastolic BP (mm Hg) 75 (7) 74 (8) t test 0.951 74 (8) 66–99
BMI (kg/m
2) 26.0 (6.7) 25.7 (6.7) t test 0.921 25.8 (7) 17–42
Total cholesterol (mmol/l) 5.1 (1.2) 4.7 (0.8) t test 0.242 4.9 (1.1) 2.9–7.6
LDL cholesterol (mmol/l) 3.3 (1.0) 2.9 (0.7) t test 0.369
HDL cholesterol (mmol/l) 1.3 (0.4) 1.2 (0.3) t test 0.568 1.3 (0.4) 0.8–2.3
Triglycerides (mmol/l) 1.0 (0.5) 0.8 (0.3) t test 0.207 3.2 (0.9) 1.3–5.1
HOMA 12.4 (10.1) 6.8 (3.1) t test 0.214 10.7 (8.9) 3.1–34.9
Adiponectin 18773 (7168) 18523 (6898) t test 0.933 18686 (6938) 7075–36623
Data reported as mean (SD) unless otherwise noted.
BMI, body mass index; BP, blood pressure; CAP, carotid artery plaque; CIMT, carotid intimal medial thickness; CRP, C-reactive
protein; DAS, disease activity score; ESR, erythrocyte sedimentation rate; HDL, high-density lipoprotein; HOMA, insulin resistance
measured by log homeostasis model assessment; LDL, low-density lipoprotein; PWV, pulse wave velocity; RA, rheumatoid
arthritis; RF, rheumatoid factor.
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they received infliximab, RM ANOVA showed a significant
reduction in arterial stiffness (PWV, p=0.004) over 56 weeks
(fig 2). However, CIMT (p=0.499), AI (p=0.265) and CAP
(x
2=4.13, p=0.88; data not shown) did not change. RA disease
activity (DAS28, tender and swollen joint counts, patient global
scores and ESR) improved significantly (p,0.05, fig 2). There
were no significant changes in systolic BP (p=0.506) or
diastolic BP (p=0.835), triglycerides (p=0.830) or adiponectin
levels (p=0.962), although HOMA (p=0.540) showed a non-
significant decrease and serum HDL (p=0.336) showed non-
significant increases (fig 3).
Influences on PWV were explored further by univariate
Pearson correlation (data not shown). PWV correlated most
strongly with age at enrolment (r=0.64, N=26, p,0.01) and,
to a lesser extent, with heart rate (r=0.39, N=70, p,0.01),
systolic BP (r=0.45, N=70, p,0.01), serum HDL (r=20.35,
N=70, p,0.01), serum triglycerides (r=0.25, N=63, p,0.05)
Figure 1 Comparison of disease activity (DAS), heart rate, systolic and diastolic blood pressure in infliximab (IFX) and placebo (Plac) groups during
the placebo controlled phase of the trial. ESR, erythrocyte sedimentation rate.
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also correlated negatively with duration of infliximab treatment
(r=20.34, N=70, p,0.01) and positively with patient global
assessment (r=0.26, N=70, p=0.03) and DAS28 (r=0.23,
N=70, p=0.06). Multivariate time-series regression modelling
found that duration of infliximab treatment (negative correla-
tion) and heart rate (positive correlation) were the only
significant influences on PWV (table 2).
DISCUSSION
This study evaluated the effect of TNFa-blocking therapy on
vascular structure in RA. The placebo controlled part of the
study was unable to assess vascular effects of infliximab due to
early drop-out of the placebo group. The post hoc analysis of
long-term treatment showed that arterial stiffness (PWV)
improved after treatment with infliximab for 56 weeks.
CIMT, AI and CAP did not change over the course of the
study. Although we showed significant improvements in
vascular stiffness, the mechanisms of this improvement remain
unclear. We measured multiple modifiable cardiovascular risk
factors but these did not change significantly during infliximab
treatment. This may reflect a type II error owing to the small
study size. However, the fact that significant changes were seen
in PWV and not in any other cardiovascular risk factor suggests
Figure 2 Post hoc analysis: trends in vascular measurements and rheumatoid arthritis disease activity (DAS) during treatment with infliximab (IFX).
Repeated measures (RM) ANOVA p values indicate the significance of the overall trend while comparison between paired time points are compared by
t tests adjusted for multiple comparisons (Bonferroni correction). ESR, erythrocyte sedimentation rate.
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significanceoftheoveralltrendwhilecomparisonsbetweenpairedtimepointsaremadebyttestadjustedformultiplecomparisons(Bonferronicorrection).BP,
blood pressure; HDL, high-density lipoprotein; HOMA, insulin resistance measured by log homeostasis model assessment; LDL, low-density lipoprotein.
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conventional risk factors.
This is the first study to demonstrate long-term improvement
in RA vascular stiffness with TNFa-blocking therapy. One small
study showed improvement in PWV with etanercept
24 while
others found no change in AI after TNFa-blocking therapy,
24 33
supporting our own work. AI measures vascular stiffness and
peripheral resistance,
34 while PWV purely reflects vascular
stiffness
20 and probably reflects the severity of atherosclerosis
and vessel wall calcification. PWV is increased in hypertension,
20
hypercholesterolaemia,
35 vasculitis
36 and RA,
24 and strongly
predicts cardiovascular events in hypertension
19 and cardiovas-
cular and all-cause mortality in diabetes
37 and hypertension.
38
The long-term improvements in vascular stiffness shown in
our study support the registry studies demonstrating improve-
ments in vascular disease in patients receiving TNFa-blocking
drugs.
12–14 Cohort studies show reductions of cardiovascular
events in patients treated with TNFa-blocking therapy.
13 The
CORRONA Registry found a reduction of cardiovascular events
in patients receiving TNFa-blocking therapy
14 that was not
evident before 6 months of treatment, with greatest benefit
after 12 months of treatment. This time course is consistent
with our findings using PWV.
Not all studies support the above findings. The British Society
for Rheumatology Biologics Register (BSRBR) demonstrated an
improvement in the incidence of myocardial infarction in
patients with RA responding to TNFa-blocking therapy within
the first 6 months compared with patients receiving traditional
disease-modifying antirheumatic drugs.
15 Two large nested case-
control studies have not found a significant improvement in the
rates of myocardial infarction
39 40 or stroke
39 in patients treated
with TNFa-blocking therapy compared with patients not
receiving this therapy. However, these observational studies
may be falsely negative due to confounding by indication.
Data regarding the effect of anti-TNF therapy on CIMT is
conflicting. CIMT has been shown to be increased in some
studies of patients with RA compared with age-matched control
subjects.
41–43 CIMT improves slowly with lipid-lowering ther-
apy. Del Porto et al found significant improvements in CIMT
after 12 months of TNFa-blocking therapy,
21 but Gonzalez-
Juanatey showed worsening of CIMT during 2–3 years of
TNFa-blocking therapy.
25 Our study may have been under-
powered to demonstrate improvements in CIMT, but it is
equally possible that anti-TNF therapy prevented increases in
CIMT that would have occurred without treatment. We also
did not evaluate plaque characteristics (softness, hardness)
which may have changed more rapidly.
Methotrexate has been shown to improve mortality in RA.
44
All patients in the present study were taking stable background
methotrexate, so any benefit on cardiovascular function seen in
this study will be due to infliximab. However, we were unable
to demonstrate synergy of methotrexate and infliximab in
relation to vascular structure as has been shown for joint disease
activity.
8–11
The major limitation of our study mainly is the study size.
Also, the lack of vascular outcome measures before 24 weeks
means that we may have missed any earlier changes to vascular
structure and stiffness, particularly if changes did in fact occur
earlier but then reverted back to baseline within the time-frame
of assessment. This study has, however, shown for the first
time that BP measures are stable over a 16-week period and do
not exhibit a placebo response. This finding is particularly
important since PWV is affected by BP. As BP remains constant,
the changes demonstrated for PWV more likely reflect true
changes in aortic stiffness.
We examined many potential mechanisms for the long-term
improvements in vascular stiffness, including novel modifiable
cardiovascular risk factors such as HOMA and adiponectin.
Adiponectin is lower in patients at increased risk of cardiovas-
cular disease.
27 Most of the modifiable cardiovascular risk factors
we measured did not correlate with vascular measures at
baseline. More importantly, we found no significant changes in
these measures over time despite significant improvements in
disease activity and vascular stiffness, suggesting that this
might have occurred at least partly independent of conventional
cardiovascular risk factors. The evidence for a role for conven-
tional risk factors in anti-TNFa-mediated cardiovascular protec-
tion is conflicting, with some work supporting
45 and other work
not supporting
46 a role for these factors. It has also been
suggested that a reduction in oxidative stress changes the
function of lipid particles,
47 but we found no changes in oxidised
LDL levels or the ratio of oxidised LDLto LDL. We are therefore
left with the enigma that vascular abnormalities are somehow
linked to chronic active RA, but the mechanisms of this link are
unclear.
In conclusion, we report that arterial stiffness improves with
long-term infliximab treatment in RA and that this seems to
occur independently of conventional cardiovascular risk factors.
These findings suggest that the combination of TNFa-blocking
therapy with methotrexate not only reduces joint damage but
also vascular ‘‘damage’’ in patients with RA. This is consistent
with recent findings of reduced mortality and cardiovascular
events after several months in patients with RA receiving
TNFa-blocking therapy.
Table 2 Multivariate analysis for influences on PWV (linear variance, random effects, GLS, accounting for
clustering within individuals)
Coefficient
p Value (95% CI) Estimate Standard error z
Duration of infliximab 20.03 0.01 23.51 ,0.001 (20.05 to 20.01)
DAS28 20.02 0.14 20.13 0.897 (20.30 to 0.26)
Heart rate 0.06 0.02 2.92 0.003 (0.02 to 0.10)
Systolic BP 0.02 0.01 1.30 0.195 (20.01 to 0.04)
Triglycerides 0.48 0.40 1.22 0.221 (20.29 to 1.27)
Constant 2.42 2.24 1.08 0.282 (21.98 to 6.81)
su 1.26
se 0.99
Rho 0.62
Number of observations=59, number of groups=26, R
2 overall 0.4129.
BP, blood pressure; DAS, disease activity score.
Extended report
Ann Rheum Dis 2009;68:1277–1284. doi:10.1136/ard.2007.086157 1283Acknowledgements: The authors thank Karen McNeill and Janine Kelleher for their
help in study coordination and data collection.
Funding: This study was supported by a grant from Centocor Pty Ltd. MW was
supported by the Arthritis Foundation of Australia.
Competing interests: BK conducts clinical trials and sits on speaker panels for
Abbott, Centocor, Schering-Plough, Bristol-Meyers-Squibb and Amgen. SPO conducts
trials for Amgen, Abbott, Centocor and Bristol-Myers-Squibb.
Ethics approval: The study was approved by the Guy’s Hospital Research Ethics
Committee and patients gave written informed consent.
REFERENCES
1. Gabriel SE, Crowson CS, Kremers HM, Doran MF, Turesson C, O’Fallon WM, et al.
Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years.
Arthritis Rheum 2003;48:54–8.
2. Jacobsson LT, Turesson C, Hanson RL, Pillemer S, Sievers ML, Pettitt DJ, et al.
Joint swelling as a predictor of death from cardiovascular disease in a population
study of Pima Indians. Arthritis Rheum 2001;44:1170–6.
3. Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S. Extent of
inflammation predicts cardiovascular disease and overall mortality in seropositive
rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol
1999;26:2562–71.
4. Del Rincon I, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of
cardiovascular events in a rheumatoid arthritis cohort not explained by traditional
cardiac risk factors. Arthritis Rheum 2001;44:2737–45.
5. Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular
feature of rheumatoid arthritis? Arthritis Rheum 2002;46:862–73.
6. Pasceri V, Yeh ET. A tale of two diseases: atherosclerosis and rheumatoid arthritis.
Circulation 1999;100:2124–6.
7. Dixon WG, Symmons DP. What effects might anti-TNFalpha treatment be expected to
have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the
role of TNFalpha in cardiovascular pathophysiology. Ann Rheum Dis 2007;66:1132–6.
8. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven
R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of
combination therapy with adalimumab plus methotrexate versus methotrexate alone
or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had
not had previous methotrexate treatment. Arthritis Rheum 2006;54:26–37.
9. Smolen JS, Van Der Heijde DM, St Clair EW, Emery P, Bathon JM, Keystone E, et al.
Predictors of joint damage in patients with early rheumatoid arthritis treated with
high-dose methotrexate with or without concomitant infliximab: results from the
ASPIRE trial. Arthritis Rheum 2006;54:702–10.
10. van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-
Gomes J, et al. Comparison of etanercept and methotrexate, alone and combined, in
the treatment of rheumatoid arthritis: two-year clinical and radiographic results from
the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006;54:1063–74.
11. Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, et al. Evidence of
radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid
arthritis patients who had no clinical improvement: a detailed subanalysis of data
from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant
therapy study. Arthritis Rheum 2005;52:1020–30.
12. Jacobsson LT, Turesson C, Nilsson JA, Petersson IF, Lindqvist E, Saxne T, et al.
Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis.
Ann Rheum Dis 2007;66:670–5.
13. Jacobsson LT, Turesson C, Gulfe A, Kapetanovic MC, Petersson IF, Saxne T, et al.
Treatmentwithtumornecrosisfactorblockersisassociatedwithalowerincidenceoffirst
cardiovasculareventsinpatientswithrheumatoidarthritis.JRh eu ma to l2005;32:1213–8.
14. Greenberg J, Lin S, Decktor D, Dabbous O, Baumgartner S, Montomery M, et al.
Association of duration of TNF antagonist treatment with reduction in cardiovascular
outcomes in RA patients (abstract). Arthritis Rheum 2006;54(9 Suppl):422.
15. Dixon WG, Watson KD, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Reduction in
the incidence of myocardial infarction in patients with rheumatoid arthritis who
respond to anti-tumor necrosis factor alpha therapy: results from the British Society
for Rheumatology Biologics Register. Arthritis Rheum 2007;56:2905–12.
16. Kobayashi K, Akishita M, Yu W, Hashimoto M, Ohni M, Toba K. Interrelationship
between non-invasive measurements of atherosclerosis: flow-mediated dilation of
brachial artery, carotid intima-media thickness and pulse wave velocity.
Atherosclerosis 2004;173:13–8.
17. Lehmann ED. Clinical value of aortic pulse-wave velocity measurement. Lancet
1999;354:528–9.
18. O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SKJ. Carotid-
artery intima and media thickness as a risk factor for myocardial infarction and stroke
in older adults. Cardiovascular Health Study Collaborative Research Group.
N Engl J Med 1999;340:14–22.
19. Boutouyrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P, et al. Aortic
stiffness is an independent predictor of primary coronary events in hypertensive
patients: a longitudinal study. Hypertension 2002;39:10–5.
20. Mitchell GF, Dunlap ME, Warnica W, Ducharme A, Arnold JM, Tardif JC, et al. Long-
term trandolapril treatment is associated with reduced aortic stiffness: the prevention
of events with angiotensin-converting enzyme inhibition hemodynamic substudy.
Hypertension 2007;49:1271–7.
21. Del Porto F, Lagana B, Lai S, Nofroni I, Tinti F, Vitale M, et al. Response to anti-
tumour necrosis factor alpha blockade is associated with reduction of carotid intima-
media thickness in patients with active rheumatoid arthritis. Rheumatology (Oxford)
2007;46:1111–5.
22. Vaudo G, Marchesi S, Gerli R, Allegrucci R, Giordano A, Siepi D, et al. Endothelial
dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann
Rheum Dis 2004;63:31–5.
23. Wong M, Toh L, Wilson A, Rowley K, Karschimkus C, Prior D, et al. Reduced arterial
elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors
and inflammation. Arthritis Rheum 2003;48:81–9.
24. Maki-Petaja KM, Hall FC, Booth AD, Wallace SM, Yasmin, Bearcroft PW, et al.
Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is
reduced by anti-tumor necrosis factor-alpha therapy. Circulation 2006;114:1185–92.
25. Gonzalez-Juanatey C, Llorca J, Garcia-Porrua C, Martin J, Gonzalez-Gay MA. Effect
of anti-tumor necrosis factor alpha therapy on the progression of subclinical
atherosclerosis in severe rheumatoid arthritis. Arthritis Rheum 2006;55:150–3.
26. Anselmi M, Garbin U, Agostoni P, Fusaro M, Pasini AF, Nava C, et al. Plasma levels
of oxidized-low-density lipoproteins are higher in patients with unstable angina and
correlated with angiographic coronary complex plaques. Atherosclerosis
2006;185:114–20.
27. Im JA, Kim SH, Lee JW, Shim JY, Lee HR, Lee DC. Association between
hypoadiponectinemia and cardiovascular risk factors in nonobese healthy adults.
Metabolism 2006;55:1546–50.
28. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The
American Rheumatism Association 1987 revised criteria for the classification of
rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
29. Ramey DR, Raynauld JP, Fries JF. The health assessment questionnaire 1992: status
and review. Arthritis Care Res 1992;5:119–29.
30. Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel
PL. Modified disease activity scores that include twenty-eight-joint counts.
Development and validation in a prospective longitudinal study of patients with
rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
31. Rabasa-Lhoret R, Bastard JP, Jan V, Ducluzeau PH, Andreelli F, Guebre F, et al.
Modified quantitative insulin sensitivity check index is better correlated to
hyperinsulinemic glucose clamp than other fasting-based index of insulin sensitivity in
different insulin-resistant states. J Clin Endocrinol Metab 2003;88:4917–23.
32. LassereM,BoersM,vanderHeijdeD,BoonenA,EdmondsJ,SaudanA,etal.Smallest
detectable difference in radiological progression. JR h e u m a t o l1999;26:731–9.
33. Van Doornum S, McColl G, Wicks IP. Tumour necrosis factor antagonists improve
disease activity but not arterial stiffness in rheumatoid arthritis. Rheumatology
(Oxford) 2005;44:1428–32.
34. Sakurai M, Yamakado T, Kurachi H, Kato T, Kuroda K, Ishisu R, et al. The relationship
between aortic augmentation index and pulse wave velocity: an invasive study.
J Hypertens 2007;25:391–7.
35. Lehmann ED, Watts GF, Gosling RG. Aortic distensibility and hypercholesterolaemia.
Lancet 1992;340:1171–2.
36. Booth AD, Wallace S, McEniery CM, Yasmin, Brown J, Jayne DR, et al. Inflammation
and arterial stiffness in systemic vasculitis: a model of vascular inflammation. Arthritis
Rheum 2004;50:581–8.
37. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-
wave velocity and its relationship to mortality in diabetes and glucose intolerance: an
integrated index of vascular function? Circulation 2002;106:2085–90.
38. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, et al. Aortic stiffness
is an independent predictor of all-cause and cardiovascular mortality in hypertensive
patients. Hypertension 2001;37:1236–41.
39. Solomon DH, Avorn J, Katz JN, Weinblatt ME, Setoguchi S, Levin R, et al.
Immunosuppressive medications and hospitalization for cardiovascular events in
patients with rheumatoid arthritis. Arthritis Rheum 2006;54:3790–8.
40. Suissa S, Bernatsky S, Hudson M. Antirheumatic drug use and the risk of acute
myocardial infarction. Arthritis Rheum 2006;55:531–6.
41. Kumeda Y, Inaba M, Goto H, Nagata M, Henmi Y, Furumitsu Y, et al. Increased
thickness of the arterial intima-media detected by ultrasonography in patients with
rheumatoid arthritis. Arthritis Rheum 2002;46:1489–97.
42. Park YB, Ahn CW, Choi HK, Lee SH, In BH, Lee HC, et al. Atherosclerosis in
rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis
Rheum 2002;46:1714–9.
43. Del Rincon I, Williams K, Stern MP, Freeman GL, O’Leary DH, Escalante A.
Association between carotid atherosclerosis and markers of inflammationi n
rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003;48:1833–40.
44. Krause D, Schleusser B, Herborn G, Rau R. Response to methotrexate treatment is
associated with reduced mortality in patients with severe rheumatoid arthritis.
Arthritis Rheum 2000;43:14–21.
45. Popa C, van den Hoogen FH, Radstake TR, Netea MG, Eijsbouts AE, den Heijer M, et
al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy
in patients with active rheumatoid arthritis. Ann Rheum Dis 2007;66:1503–15.
46. Nurmohamed MT. Atherogenic lipid profiles and its management in patients with
rheumatoid arthritis. Vasc Health Risk Manag 2007;3:845–52.
47. Chenevard R, Hurlimann D, Bechir M, Enseleit F, Spieker L, Hermann M, et al.
Selective COX-2 inhibition improves endothelial function in coronary artery disease.
Circulation 2003;107:405–9.
Extended report
1284 Ann Rheum Dis 2009;68:1277–1284. doi:10.1136/ard.2007.086157